Showing results (311-320 of 584) with videos related to
Sort By:
Pageof 59
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief ReportSai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.Cancer Chemotherapy and Pharmacology|February 24, 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesDavid Planchard, Kathryn H Brown, Dong-Wan Kim, et al.Nature Reviews. Clinical Oncology|July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challengesGiannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancerNermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.Frontiers in Oncology|April 14, 2022
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung CancerBrendan Knapp, Laura Mezquita, Siddhartha Devarakonda, et al.Cancer Biomarkers : Section a of Disease Markers|November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancerJulien Adam, Tony Sourisseau, Ken A Olaussen, et al.Journal of Telemedicine and Telecare|February 8, 2024
Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemicMyrto Kastrisiou, Maryam Karimi, Evangelos Aa Christou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sitesCarlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.European Journal of Cancer (Oxford, England : 1990)|March 1, 2017
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoidsIvana Sullivan, Gwénaël Le Teuff, Joël Guigay, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung CancerDavid Planchard, Michael J Boyer, Jong-Seok Lee, et al.Pageof 59